AltruBio Inc.

[Not Yet Scheduled]
AltruBio is a clinical stage biopharmaceutical company with the strength in developing novel therapeutics for the treatment of immunological diseases with high unmet medical needs. Based on unique insights into the regulation of immune homeostasis, AltruBio's pipeline is focused on the depletion of unwanted activated T-cells with clinical proof of mechanism in four autoimmune and inflammatory diseases.
AltruBio has discovered and developed the first-in-class checkpoint regulator PGSL-1 agonist antibodies which can be leveraged as a technology platform to address the needs in many immunological and inflammatory diseases.
Under the leadership of biotech veterans, the company has completed the Series A in 2Q2021 and is aimed towards the next set of project milestones around 4Q2022.
Company Type:
Privately Funded Company
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Lead Product in Development:
neihulizumab
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO and President
AltruBio, Inc.